
Sonio, a wholly-owned subsidiary of Samsung Medison Co., Ltd since 2024, is a highly customizable workflow and practice management solution powered by AI for automation, efficiency, and quality control. "Sonio AI-enhanced¹ software empowers ultrasound practitioners and readers. Sonio assists them in performing every prenatal examination to their highest quality standards, ensuring the completeness of each examination, streamlining their workflow, and in prenatal diagnosis. Sonio is based on over five years of research and collaboration between leading experts in fetal medicine and AI. ¹AI-enhancement is provided by FDA 510(k) cleared Sonio Detect product * Applicable to V1 only, Data enclosed at Sonio **See table 6 in the 510k summary: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240406.pdf

Sonio, a wholly-owned subsidiary of Samsung Medison Co., Ltd since 2024, is a highly customizable workflow and practice management solution powered by AI for automation, efficiency, and quality control. "Sonio AI-enhanced¹ software empowers ultrasound practitioners and readers. Sonio assists them in performing every prenatal examination to their highest quality standards, ensuring the completeness of each examination, streamlining their workflow, and in prenatal diagnosis. Sonio is based on over five years of research and collaboration between leading experts in fetal medicine and AI. ¹AI-enhancement is provided by FDA 510(k) cleared Sonio Detect product * Applicable to V1 only, Data enclosed at Sonio **See table 6 in the 510k summary: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240406.pdf
Founded: 2020 (Paris)
Product: AI-enabled prenatal ultrasound workflow software (Sonio Detect)
Regulatory status: Sonio Detect: FDA 510(k) clearance and CE marked
Exit / M&A: Acquired by Samsung Medison in 2024
Recent funding: Series A $14M (2023)
Prenatal ultrasound quality, workflow automation, and reporting in OB-GYN practice.
2020
Software Development
€5,000,000
Announced June 2022
€10,000,000
Reported as €2.5M grant + €7.5M equity
$14,000,000
Participation from Elaia, Bpifrance, OneRagtime and angel investors
Company became a wholly-owned subsidiary of Samsung Medison
“Includes institutional backers (Cross Border Impact Ventures, Elaia, Bpifrance, OneRagtime) and EIC support”
| Company |
|---|
Sonio is dedicated to improving women's and children's health by enhancing access and quality of care through technological innovation, medical expertise, and collective intelligence. Each year, 140 million children are born, with birth defects affecting 1 in 33 births in developed countries. In 50% of cases, these defects are not detected during prenatal examinations, which adds stress for future parents and places heavy responsibilities on healthcare professionals.
Sonio was developed through five years of collaboration between renowned experts from Necker Hospital and Ecole Polytechnique. The company utilizes artificial intelligence to enhance prenatal screening and diagnosis, aiming to become the reference tool for practitioners to improve screening, reduce diagnostic errors, and optimize the medical path for pregnant women.
Location: Paris, Île-de-France, France
Employment Type: Full-time
Department: Technology
Workplace Type: Hybrid
We are currently building our next generation of products that provide real-time assistance to practitioners during fetal ultrasound examinations. The systems we develop interface with ultrasound machines, stream imaging data to our cloud, interpret data and images using AI/ML, and push results back to the practitioner’s interface in near real-time.
We do not require a formal resume if you have an up-to-date LinkedIn profile or notable GitHub projects. Our objective is to complete the process from the first chat to an offer in no longer than a month. We aim to provide an answer to every application within a week. If you have not heard from us, please follow up at careers@sonio.ai.